RU2013157188A - Композиции св-183,315 и относящиеся к ним способы - Google Patents
Композиции св-183,315 и относящиеся к ним способы Download PDFInfo
- Publication number
- RU2013157188A RU2013157188A RU2013157188/15A RU2013157188A RU2013157188A RU 2013157188 A RU2013157188 A RU 2013157188A RU 2013157188/15 A RU2013157188/15 A RU 2013157188/15A RU 2013157188 A RU2013157188 A RU 2013157188A RU 2013157188 A RU2013157188 A RU 2013157188A
- Authority
- RU
- Russia
- Prior art keywords
- solid preparation
- sucrose
- weight
- aqueous solution
- trehalose
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 4
- 238000002360 preparation method Methods 0.000 claims abstract 29
- 239000007787 solid Substances 0.000 claims abstract 29
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract 23
- 229930006000 Sucrose Natural products 0.000 claims abstract 23
- 239000005720 sucrose Substances 0.000 claims abstract 23
- 239000007864 aqueous solution Substances 0.000 claims abstract 17
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract 11
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract 11
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract 11
- 230000015572 biosynthetic process Effects 0.000 claims abstract 11
- 238000004108 freeze drying Methods 0.000 claims abstract 5
- 239000007921 spray Substances 0.000 claims abstract 5
- 239000002775 capsule Substances 0.000 claims abstract 4
- 239000006186 oral dosage form Substances 0.000 claims abstract 4
- 238000001694 spray drying Methods 0.000 claims abstract 4
- 238000001035 drying Methods 0.000 claims abstract 3
- 229920002307 Dextran Polymers 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims abstract 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 7
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 239000000377 silicon dioxide Substances 0.000 claims 4
- 235000012239 silicon dioxide Nutrition 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000463 material Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490584P | 2011-05-26 | 2011-05-26 | |
| US61/490,584 | 2011-05-26 | ||
| PCT/US2012/039476 WO2012162567A1 (en) | 2011-05-26 | 2012-05-24 | Cb-183,315 compositions and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013157188A true RU2013157188A (ru) | 2015-07-10 |
Family
ID=46208839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013157188/15A RU2013157188A (ru) | 2011-05-26 | 2012-05-24 | Композиции св-183,315 и относящиеся к ним способы |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20130109633A1 (enExample) |
| EP (1) | EP2714012A1 (enExample) |
| JP (1) | JP2014515371A (enExample) |
| KR (1) | KR20140037877A (enExample) |
| CN (1) | CN103687589A (enExample) |
| AR (1) | AR086576A1 (enExample) |
| BR (1) | BR112013030369A2 (enExample) |
| CA (1) | CA2837174A1 (enExample) |
| MX (1) | MX2013013760A (enExample) |
| RU (1) | RU2013157188A (enExample) |
| TW (1) | TW201300124A (enExample) |
| WO (1) | WO2012162567A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10647746B2 (en) | 2016-04-08 | 2020-05-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
| WO2017173932A1 (en) * | 2016-04-08 | 2017-10-12 | Versitech Limited | Antibacterial cyclic lipopeptides |
| US11667674B2 (en) | 2016-04-08 | 2023-06-06 | Versitech Limited | Antibacterial cyclic lipopeptides |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2394313A1 (en) * | 1999-12-15 | 2001-06-21 | Cubist Pharmaceuticals, Inc. | Novel lipopeptides as antibacterial agents |
| CA2413251C (en) * | 2000-06-21 | 2012-06-12 | Cubist Pharmaceuticals, Inc. | Compositions and methods to improve the oral absorption of antimicrobial agents |
| KR20090122469A (ko) * | 2000-12-18 | 2009-11-30 | 큐비스트 파마슈티컬즈 인코포레이티드 | 정제된 리포펩티드의 제조 방법 |
| JP2008519848A (ja) * | 2004-11-12 | 2008-06-12 | キュービスト ファーマシューティカルズ， インコーポレイテッド | 抗感染性リポペプチド |
| US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| DK2379580T3 (da) * | 2008-12-22 | 2014-01-20 | Cubist Pharm Inc | Hidtil ukendte antibakterielle midler til behandling af gram-positive infektioner |
| JP5491119B2 (ja) * | 2009-10-02 | 2014-05-14 | 日東電工株式会社 | 薬物含有微粒子を含む医薬組成物およびその製造方法 |
| CN102060914B (zh) * | 2009-11-13 | 2014-09-17 | 华东理工大学 | 海洋芽孢杆菌b-9987产脂肽类化合物及其制备和应用 |
| WO2011062676A1 (en) * | 2009-11-23 | 2011-05-26 | Eagle Pharmaceuticals, Inc. | Formulations of daptomycin |
| PT2504353T (pt) * | 2009-11-23 | 2018-10-18 | Cubist Pharmaceuticals Llc | Composições de lipopéptido e métodos relacionados |
-
2012
- 2012-05-24 WO PCT/US2012/039476 patent/WO2012162567A1/en not_active Ceased
- 2012-05-24 RU RU2013157188/15A patent/RU2013157188A/ru not_active Application Discontinuation
- 2012-05-24 BR BR112013030369A patent/BR112013030369A2/pt not_active IP Right Cessation
- 2012-05-24 MX MX2013013760A patent/MX2013013760A/es unknown
- 2012-05-24 JP JP2014512126A patent/JP2014515371A/ja active Pending
- 2012-05-24 KR KR1020137033768A patent/KR20140037877A/ko not_active Withdrawn
- 2012-05-24 CA CA2837174A patent/CA2837174A1/en not_active Abandoned
- 2012-05-24 CN CN201280025551.2A patent/CN103687589A/zh active Pending
- 2012-05-24 EP EP12725988.5A patent/EP2714012A1/en not_active Withdrawn
- 2012-05-25 US US13/481,009 patent/US20130109633A1/en not_active Abandoned
- 2012-05-25 TW TW101118841A patent/TW201300124A/zh unknown
- 2012-05-28 AR ARP120101868A patent/AR086576A1/es unknown
-
2013
- 2013-10-07 US US14/047,701 patent/US20140135273A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2714012A1 (en) | 2014-04-09 |
| WO2012162567A1 (en) | 2012-11-29 |
| JP2014515371A (ja) | 2014-06-30 |
| TW201300124A (zh) | 2013-01-01 |
| BR112013030369A2 (pt) | 2016-12-13 |
| US20130109633A1 (en) | 2013-05-02 |
| US20140135273A1 (en) | 2014-05-15 |
| MX2013013760A (es) | 2014-01-08 |
| CN103687589A (zh) | 2014-03-26 |
| KR20140037877A (ko) | 2014-03-27 |
| CA2837174A1 (en) | 2012-11-29 |
| AR086576A1 (es) | 2014-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011107970A3 (en) | Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect. | |
| JP2009530415A5 (enExample) | ||
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| EA201391758A1 (ru) | Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты | |
| JP2016535065A5 (enExample) | ||
| NZ707328A (en) | Virus-containing formulation and use thereof | |
| NZ759512A (en) | Delayed release compositions of linaclotide | |
| FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
| JP2010534220A5 (enExample) | ||
| HRP20171512T1 (hr) | Derivati betulina | |
| RU2015151938A (ru) | Таблетируемый препарат (4'-трифторметилфенил)амида (z)-2-циано-3-гидрокси-бут-2-еноевой кислоты с улучшенной устойчивостью | |
| JP2016516721A5 (enExample) | ||
| JP2015007131A5 (enExample) | ||
| JP2013537212A5 (enExample) | ||
| EA201190161A1 (ru) | Способ получения твердых лекарственных форм солифенацина и его фармацевтически приемлемых солей для перорального введения | |
| RU2017129340A (ru) | Композиции nеisseria мeningitidis и способы их получения | |
| WO2012087256A3 (en) | Pharmaceutical capsule formulations | |
| WO2011056785A3 (en) | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients | |
| RU2015138710A (ru) | Жевательная композиция для перорального приема и способ ее получения | |
| WO2009084041A3 (en) | Pharmaceutical compositions of dexibuprofen | |
| JP2010536837A5 (enExample) | ||
| RU2013105216A (ru) | ИНЪЕКЦИОННАЯ ФОРМА 5α-АНДРОСТАН-3β,5,6β-ТРИОЛА И СПОСОБ ЕЕ ПОЛУЧЕНИЯ | |
| UA105285C2 (uk) | Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання | |
| RU2018126670A (ru) | Фармацевтическая композиция для лечения гиперплазии предстательной железы | |
| JP2014515371A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20161024 |